Plasmid DNA is circular DNA molecules occurring in bacteria and other cells. They are used as a tool for cloning genes and in genetic engineering as they are able to self-replicate independently of the chromosomal DNA. Plasmid DNA are considered invaluable to scientific research and have applications in gene therapy, DNA vaccines, genetic engineering, and more. Plasmid DNA is used as a therapeutic agent and as an expression or delivery system for gene therapy. They help deliver therapeutic genes into patients in need of treatment.
The global Plasmid DNA Manufacturing Market is estimated to be valued at Us$ 901.2 Bn in 2023 and is expected to exhibit a CAGR Of 4.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Gene therapy is a booming biopharmaceutical industry projected to reach over US$ 10 billion by 2030. The opportunity for growth in gene therapy provided by plasmid DNA is immense. As more gene therapy clinical trials are approved and treatments are commercialized, the demand for high quality and GMP grade plasmid DNA will surge significantly. Plasmid DNA forms the foundation of all gene therapy and DNA vaccine products providing an optimal medium to alter genetic code. With over 3000 gene therapy clinical trials ongoing worldwide for various genetic and acquired diseases, plasmid DNA manufacturing will play a vital role in fueling the gene therapy revolution and transforming patient care.
Porter's Analysis
Threat of new entrants: Low capital requirements and lack of proprietary technology pose a low threat of new entrants in the plasmid DNA manufacturing market.
Bargaining power of buyers: Large pharmaceutical and biotech companies have significant bargaining power over plasmid DNA manufacturers due to their bulk buying ability.
Bargaining power of suppliers: Raw material suppliers have medium bargaining power due to accessibility of raw materials for plasmid DNA.
Threat of new substitutes: No viable substitute exists for plasmid DNA used in genetic engineering and gene therapy research and development.
Competitive rivalry: Intense competition exists among existing plasmid DNA manufacturers due to their focus on expanding production capacity and capabilities.
SWOT Analysis
Strengths: Growing R&D investment in gene therapy and vaccines.
Weaknesses: Regulatory compliance requirements increase costs and complex manufacturing processes.
Opportunities: Increasing plasmid DNA demand for COVID-19 vaccine development.
Threats: Challenges in developing high-yield purity and potency plasmid DNA products.
Key Takeaways
The
Global Plasmid DNA Manufacturing Market Demand is expected to witness high growth over the forecast period of 2023 to 2030 driven by increasing investment in gene therapy and DNA vaccine development. The global Plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030.
The North America region currently dominates the market attributed to presence of leading biopharma companies and gene therapy research.
Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevro. Cobra Biologics specializes in cGMP manufacturing of plasmid DNA while Aldevro focuses on process development and manufacturing services for plasmid DNA.
Get more insights on this topic :
Comments
0 comment